Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 5
2004 1
2007 1
2009 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study.
Madan M, Nikhil J, Hellkamp AS, Pieper KS, Labinaz M, Cohen EA, Buller CE, Cantor WJ, Seidelin P, Ducas J, Carere RG, Natarajan MK, O'Shea JC, Tcheng JE; ESPRIT Investigators. Madan M, et al. Can J Cardiol. 2009 Aug;25(8):e269-72. doi: 10.1016/s0828-282x(09)70120-5. Can J Cardiol. 2009. PMID: 19668787 Free PMC article.
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Dery JP, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, Gibson CM, Tolleson TR, O'Shea JC, Tcheng JE; ESPRIT Investigators. Dery JP, et al. Catheter Cardiovasc Interv. 2007 Jul 1;70(1):43-50. doi: 10.1002/ccd.21059. Catheter Cardiovasc Interv. 2007. PMID: 17203469 Clinical Trial.
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
Fernandes LS, Tcheng JE, O'Shea JC, Weiner B, Lorenz TJ, Pacchiana C, Berdan LG, Maresh KJ, Joseph D, Madan M, Mann T, Kilaru R, Hochman JS, Kleiman NS; ESPRIT investigators. Fernandes LS, et al. J Am Coll Cardiol. 2002 Sep 18;40(6):1085-91. doi: 10.1016/s0735-1097(02)02120-4. J Am Coll Cardiol. 2002. PMID: 12354432 Free article.
Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).
Labinaz M, Madan M, O'Shea JO, Kilaru R, Chin W, Pieper K, McGuire DK, Saucedo JF, Talley JD, Lui H, Kitt MM, Califf RM, Tcheng JT; ESPRIT Investigators. Labinaz M, et al. Am J Cardiol. 2002 Sep 15;90(6):585-90. doi: 10.1016/s0002-9149(02)02560-2. Am J Cardiol. 2002. PMID: 12231081 Clinical Trial.
11 results